Figure 1From: B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumaband implications for study designTreatment protocol of the BELONG study. AZT, azathioprene; CYC,cyclophosphamide; EL, EUROLUPUS; LN, lupus nephritis; MMF, mycophenolate mofetil;OCR, ocrelizumab; ORR, overall renal response; PBO, placebo.Back to article page